ISOFLURANE
Cancer, Other
Peter MacCallum Cancer Centre, AustraliaSmall moleculePhase 4 / ApprovedDormant
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 51/ 100
- Competitive Position
- 95/ 100
Competitive context
1412 Active assets in the Cancer, Other cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nabiximols Jazz Pharmaceuticals | Phase 3 | BBB |
Vitamin B6 M.D. Anderson Cancer Center | Phase 4 | BB |
Inno-206 M.D. Anderson Cancer Center | Phase 2 | BB |
Desflurane Peter MacCallum Cancer Centre, Australia | Phase 4 | BB |
Rivoceranib Jiangsu HengRui Medicine Co., Ltd. | Phase 4 | BB |
View all 50 →
Same molecule, other indications
ISOFLURANE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →